McKesson Corporation vs Nutanix Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Nutanix Inc trades at $74.63 (market cap $19.78B). The key difference: McKesson Corporation is far larger — about 5.5× Nutanix Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Nutanix Inc for 17 Days on average.
| MCK | NTNX | |
|---|---|---|
Market Cap | $108.46B | $19.78B |
Volume | 712,607 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $995.69 | $74.63 |
52-Week Low | $725.17 | $34.41 |
Typical Hold Time | 74 Days | 17 Days |
Enterprise Value | $115.00B | $18.94B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $76.11. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.60 surpassing the $0.49 expectation. Revenue growth is robust, projected to rise from $2.54 billion in 2025 to $2.9 billion in 2026, while net income margin expanded significantly to 52.81%.
The outlook remains positive driven by strong execution, external storage partnerships, and AI growth initiatives, though high valuation multiples like EV/EBITDA of 46.22 and negative ROE of -395.76% pose risks. Investor sentiment is buoyed by recent Gartner recognitions and earnings beats, but supply chain pressures and competitive threats require monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →